GH Secretagogues in 'Optimization'
Sermorelin, CJC-1295, Ipamorelin, MK-677, Indirect GH Boosting Marketed to Aging Men
Evidence grade 2 of 5, Thin. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- No FDA approval for anti-aging; several are compounded, research-only, or unapproved; MK-677 (ibutamoren) is an unapproved investigational drug
Reference only. Not medical advice.
What can go wrong
Documented or expected effects include insulin resistance and elevated blood glucose (especially MK-677), fluid retention and edema, arthralgia, increased appetite/weight gain, and lethargy. Purity is a major hazard: compounded and research-grade peptides vary in identity and contamination. Long-term safety and any cancer-relevant IGF-1 effects are unstudied in this use.
This is something to take to a clinician. The Atlas can tell you what is known about gh secretagogues in 'optimization' in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
Longevity and men's clinics increasingly favor GH secretagogues, agents that prod the pituitary to release the body's own GH, over injected GH itself, framing them as safer and more 'physiologic.' They include GHRH analogs (sermorelin, CJC-1295), ghrelin/GH-releasing peptides (ipamorelin, GHRP-2/6), and the oral non-peptide MK-677 (ibutamoren). All raise GH/IGF-1 and can shift body composition, but none is FDA-approved for aging, human longevity outcomes are absent, and they inherit the GH axis's metabolic liabilities (insulin resistance, fluid retention, appetite). Many are sold via compounding pharmacies or gray-market 'research chemical' channels.
The 'gentler' GH pitch, same axis, same unanswered safety questions.
What people take it for
These are the reasons people give for taking it. They are not effects it has been shown to have.
Combinations named above are how people use these compounds together, under names the community gave them. The combinations themselves have not been studied. Evidence for one compound is not evidence for a pair.
How it is supposed to work
GHRH analogs (sermorelin, CJC-1295) bind pituitary GHRH receptors to amplify GH release; ipamorelin and GHRP compounds and MK-677 act on the ghrelin/GH-secretagogue receptor to trigger GH pulses while stimulating appetite. The pitch is that pulsatile, feedback-preserving stimulation is 'more natural' than exogenous GH, but the downstream IGF-1 elevation and its metabolic consequences are the same.
Same axis, same liabilities
Whatever the upstream route, sustained elevation of GH/IGF-1 carries the GH axis's problems: MK-677 in trials raised IGF-1 but also worsened insulin sensitivity and caused edema and increased appetite; a notable trial in older adults with hip fracture was complicated by congestive heart failure signals. 'Physiologic' framing does not exempt these agents from the GH-related concerns, and human longevity benefit remains entirely unproven.
Safety in detail
This intervention involves significant physiological effects and requires evaluation and monitoring by a qualified physician. GH secretagogues are unapproved for anti-aging, frequently compounded or gray-market, and carry documented metabolic risks.
What has to be monitored
The bloodwork this needs, and the reason it belongs with a clinician rather than a website.
- IGF-1 levels
- Fasting glucose / HbA1c
- Weight and fluid status
- Source verification / purity concerns
What people get wrong
Often saidSecretagogues are a safe, natural alternative to GH
ActuallyThey elevate the same GH/IGF-1 axis with the same metabolic liabilities (insulin resistance, edema) and have no human longevity data; 'natural' describes the trigger, not the consequence.
Often saidMK-677 is a proven anti-aging compound
ActuallyMK-677 (ibutamoren) is an unapproved investigational drug; trials showed IGF-1 increases alongside worsened insulin sensitivity and edema, and no longevity benefit.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
What we do not know
- Do secretagogues produce any durable functional benefit beyond body composition in aging men?
- What are the long-term cardiometabolic and oncologic consequences of chronic IGF-1 elevation by these routes?
At a glance
- Classes
- GHRH analogs; ghrelin-receptor agonists; oral MK-677
- Examples
- Sermorelin, CJC-1295, ipamorelin, GHRP-2/6, MK-677
- Effect
- Raise endogenous GH/IGF-1 pulses
- FDA status
- None approved for anti-aging; MK-677 investigational
- Longevity data
- None in humans
- Common channel
- Compounding pharmacies, research-chemical gray market
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about GH Secretagogues in 'Optimization'. A short entry is not a safe entry.
- Timeline. We have not built the dated record of research and regulatory events.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
- Where we land. We have not taken a position on this yet.
Sources
No sources recorded for this entry yet. Nothing on this page can be checked against a citation until that changes, so treat it as a summary awaiting its evidence.